Title:
ANTI-CD39 ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/182530
Kind Code:
A1
Abstract:
Obtained is an excellent anti-CD39 antibody. Provided is an antibody or an antigen-binding fragment that binds to CD39, and contains heavy-chain CDRs 1-3 and light-chain CDRs 1-3 containing a specific amino acid sequence. This antibody may be a neutralizing antibody against CD39. This antibody may have the ability to inhibit malignant tumor proliferation.
More Like This:
Inventors:
NAKAMURA NORIHIRO (JP)
MIE MOTOYA (JP)
OBONAI TOSHIFUMI (JP)
BAN HARUKA (JP)
MATSUMOTO NORIKO (JP)
SHIRAISHI MAMORU (JP)
MATSUMURA HARUKA (JP)
MIE MOTOYA (JP)
OBONAI TOSHIFUMI (JP)
BAN HARUKA (JP)
MATSUMOTO NORIKO (JP)
SHIRAISHI MAMORU (JP)
MATSUMURA HARUKA (JP)
Application Number:
PCT/JP2023/012119
Publication Date:
September 28, 2023
Filing Date:
March 27, 2023
Export Citation:
Assignee:
BRIGHTPATH BIOTHERAPEUTICS CO LTD (JP)
International Classes:
C12N15/13; A61K31/282; A61K31/337; A61K31/475; A61K31/513; A61K31/519; A61K31/7068; A61K39/395; A61P35/00; A61P37/04; A61P43/00; C07D239/553; C07D305/14; C07D487/04; C07D519/04; C07H19/073; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
| WO2021056610A1 | 2021-04-01 |
Foreign References:
| JP2020530289A | 2020-10-22 | |||
| US20170335007A1 | 2017-11-23 |
Attorney, Agent or Firm:
SK INTELLECTUAL PROPERTY LAW FIRM et al. (JP)
Download PDF: